Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
Results show improved insulin sensitivity and lower glucose levels
without the side effects of current therapies
“This preliminary data confirms that a PPAR-sparing thiazolidinedione (TZD) can improve insulin sensitivity and lower glucose similar to a traditional TZD,” said Dr.
Nearly 100 patients participated in this double-blind, placebo and active-controlled, multicenter clinical trial conducted in
Similar to Actos, MSDC-0160 lowered the circulation of fatty acids and significantly increased good (HDL) cholesterol. Unlike Actos, MSDC-0160 did not decrease the levels of circulating blood cells and did not produce an increase in body weight.
Complications from the leading type 2 diabetic therapies include weight gain and edema as well as the potential for congestive heart failure and bone loss.
“Our drug development program focuses on a different molecular target,” said Colca. “We believe that selective activation of the novel mitochondrial target will produce a significantly improved safety profile for individuals with type 2 diabetes. If the results of this study can be successfully extended to longer trials, we might be able to achieve our long-term goal of a therapeutic option that could be used early in the course of the disease to prevent the otherwise inexorable progression of diabetes and its complications.”
“We are pleased that our lead compound performed so well in the Phase IIa study,” said
Additional safety and expanded efficacy data will be gathered in a 90-day, multinational Phase IIb study that is planned for late 2009.
According to the American Diabetes Association, approximately
There were 1.6 million new cases of diabetes in
Metabolic Solutions Development Company (www.msdrx.com), based in
The company’s scientific strategy is built on a historical understanding of insulin-sensitizing thiazolidinediones (TZDs) and its unique insight into the mechanism of insulin-sensitizing pharmacology. The company believes that the result will be a new generation of superior, safer drug therapies.
CONTACT: Nick Wasmiller Seyferth & Associates Inc. 1-800-435-9539 email@example.com
SOURCE Metabolic Solutions Development Company